1. Delcroix M, Howard L. Pulmonary arterial hypertension: the burden of disease and impact on quality of life. Eur Respir Rev. 2015;24:621–9.
2. Mandras SA, Gilkin RJ, Pruett JA, et al. Pulmonary arterial hypertension: progress and challenges in the modern treatment era. Am J Manag Care. 2014;20(9):S191–9.
3. Asaki T, Kuwano K, Morrison K, et al. Selexipag: an oral and selective IP prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. J Med Chem. 2015;58(18):7128–37.
4. Actelion Pharmaceuticals US Inc. UPTRAVI® (selexipag) tablets, for oral use: US prescribing information. 2015. http://www.fda.gov/ . Accessed 5 Jan 2016.
5. FirstWord Pharma. Actelion receives Health Canada approval for Uptravi (selexipag) for the long-term treatment of pulmonary arterial hypertension. 2016. http://www.firstwordpharma.com/node/1353734#axzz3yTk90Lnp . Accessed 28 Jan 2016.